Avanir Pharmaceuticals will pay $20 million up front to license the North American rights for an inhaled migraine drug from OptiNose, but the product candidate has not been tested against generic intranasal therapies to prove that its rapid onset of pain relief is a truly differentiating factor.
Aliso Viejo, California-based Avanir said AVP-825 – a dry powder sumitriptan formulation delivered by OptiNose's breath-powered intranasal device – is...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
